Article
MicroRNAs as the pivotal regulators of Temozolomide resistance in glioblastoma
2 Jul 2024
Abstract excerpt
Glioblastoma (GBM) is an aggressive nervous system tumor with a poor prognosis. Although, surgery, radiation therapy, and chemotherapy are the current standard protocol for GBM patients, there is still a poor prognosis in these patients. Temozolomide (TMZ) as a first-line therapeutic agent in GBM can easily cross from the blood-brain barrier to inhibit tumor cell proliferation. However, there is a high rate of...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
